home All News open_in_new Full Article
Is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms in China?
today 4 w. ago attach_file Economics
attach_file
Economics
attach_file
Economics
1 week ago
As tariffs hit China, ‘bold moves’ by foreign firms may bolster market share, US CEO says
attach_file
Economics
attach_file
Politics
attach_file
Events
attach_file
Economics
attach_file
Economics
ID: 3399020030